Here are the latest stories being discussed in biopharma today:

Academic-entrepreneur model changes as pioneer steps down

Stuart Schreiber, co-founder of the Broad Institute of Harvard and MIT, has resigned from the institute to launch Arena BioWorks, causing ripples throughout Boston’s elite research institutions. The organization is a $500 million experiment, blending a university lab, a drug company, and a venture capital fund with five billionaires backing it. Arena BioWorks is viewed as a bid to attract academics who are frustrated with grant applications and university conflict-of-interest rules.

2seventy bio sells R&D unit to Regeneron for $5M

2seventy bio is liquidating its entire R&D pipeline, resulting in staff cuts and a new CEO. 2seventy plans to sell its R&D infrastructure and assets, which includes 160 employees in Cambridge, MA, and Seattle, to Regeneron. After the transaction with Regeneron completes, the employee count will go down from about 280 to 65.

Gilead and Kite reduce Yescarta manufacturing duration

Gilead and Kite have received FDA approval to shorten their Yescarta manufacturing process from 16 days to 14 days. This will allow for quicker production